Morning Seminar September 28, 2006

Pediatr Blood Cancer. 2004 Dec;43(7):770-6.
A new clinical score for disease activity in Langerhans cell histiocytosis.
Donadieu J, Piguet C, Bernard F, Barkaoui M, Ouache M, Bertrand Y, Ibrahim H, Emile JF, Hermine O, Tazi A, Genereau T, Thomas C.

Morning Seminar September 26, 2006

Guideline for childhood bronchial asthma.

Morning Seminar September 21, 2006

J Clin Oncol. 2006 Aug 20;24(24):3852-7.
Suicidal ideation and attempts in adult survivors of childhood cancer.
Recklitis CJ, Lockwood RA, Rothwell MA, Diller LR.

Morning Seminar September 15, 2006

N Engl J Med. 2000 Apr 6;342(14):998-1006.
Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui CH, Masera G.

Blood. 2005 Jul 15;106(2):458-63.
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Wassmann B, Pfeifer H, Stadler M, Bornhauser M, Bug G, Scheuring UJ, Bruck P, Stelljes M, Schwerdtfeger R, Basara N, Perz J, Bunjes D, Ledderose G, Mahlberg R, Binckebanck A, Gschaidmeier H, Hoelzer D, Ottmann OG.

J Clin Oncol. 2006 Jan 20;24(3):460-6.
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R; Japan Adult Leukemia Study Group.

Morning Seminar August 31, 2006

J Clin Oncol. 2006 Jul 20;24(21):3415-22.

Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Soft Tissue Sarcoma Committee of the Children's Oncology Group; Lager JJ, Lyden ER, Anderson JR, Pappo AS, Meyer WH, Breitfeld PP.

Morning Seminar August 29, 2006

Bone Marrow Transplant. 2006 May;37(10):961-5.

Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist.

Funke VA, de Medeiros CR, Setubal DC, Ruiz J, Bitencourt MA, Bonfim CM, Neto JZ, Pasquini R.